Name Sayyad Hameeda bee Order PTGOC2600342438

Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM

Contact 7675949007 Sample Accepted 22-Jul-25 / 01:55 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 03:27 PM
Referral Doctor Self Report Status Provisional
Blood Glucose, Fasting
Department of Clinical Biochemistry
SampleType: FASTING SODIUM FLUORIDE PLASMA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Glucose - Fasting 78 mg/dL 70-100

Method: Hexokinase

Criteria for the diagnosis of diabetes

a) Fasting Plasma Glucose >=126 mg/dL (7.0 mmol/L).
or
b) Hemoglobin A1C >=6.5% (48 mmol/mol).
or
c) In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >=200 mg/dL (11.1 mmol/L).
Note:
*In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate
test samples

Criteria defining prediabetes*

a) Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG).
or
b) Hemoglobin A1C 5.7–6.4% (39–47 mmol/mol).
Note:
*For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at the
higher end of the range.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 1 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 12:20 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 02:44 PM
Referral Doctor Self Report Status Provisional
Hemoglobin A1c
Department of Clinical Biochemistry
SampleType: Whole Blood EDTA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Hemoglobin A1c 5.6 % 0-5.7

Method: HPLC

Interpretation of Results
Result (%) Interpretation
< 5.7 (<39 mmol/mol) : Normal
5.7 - 6.4 (39-47 mmol/mol) : Prediabetes
>=6.5 (48 mmol/mol) : Diabetes
Glycemic Control in Diabetic Patients
Result (%) Interpretation
< 7.0 Good control
7.0 -8.0 Inadequate control
> 8.0 Poor control
Note:
• Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the HbA1C
result does not correlate with the patient’s blood glucose levels.
• Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD
or advanced microvascular complications, hypoglycaemia unawareness and individual patient considerations.

Clinical significance
• This test is diagnostic in a patient with classic symptoms of hyperglycemia or Hyperglycemic crisis.
• HbA1c is used for monitoring diabetic control. It reflects the mean plasma glucose over 8-12 weeks.
• Trends in HbA1c are a better indicator of diabetic control than a solitary test.
• Any sample with >15% HbA1c should be suspected of having a hemoglobin variant, especially in a non-diabetic patient.
• Results below 4% should prompt additional studies to determine the possible presence of variant hemoglobin.
• Values may not be comparable with different methodologies and even different laboratories using same methodology.
• HbA1c target in pregnancy is to attain level <6 % .
Reference : American Diabetes Association (ADA) - Standards of Medical Care in Diabetes 2022

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 2 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 12:20 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 02:44 PM
Referral Doctor Self Report Status Provisional
Hemoglobin A1c
Department of Clinical Biochemistry
SampleType: Whole Blood EDTA

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 3 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 01:42 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 07:56 PM
Referral Doctor Self Report Status Provisional
Lipid Profile
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Cholesterol - Total 164 mg/dL 0-200

Method: Cholesterol Oxidase Peroxidase

Cholesterol - HDL 49 mg/dL 40-60

Method: Enzymatic Immuno Inhibition

Cholesterol - LDL 102 mg/dL 0-100

Method: Calculated

Cholesterol VLDL 13 mg/dL 5 - 40

Method: Calculated

Cholesterol Total/HDL Ratio 3.3 4-6

Method: Calculated

Cholesterol LDL/HDL Ratio 2.1 1.5 - 3.6

Method: Calculated

Triglycerides 66 mg/dL 0-150

Method: GPO POD

Interpretation of results
Risk Stratification Total Cholesterol LDL Cholesterol Non-HDL Cholesterol Triglyceride
Optimal <200 <100 <130 <150
Above Optimal 100-129 130-159 130-159
Borderline High 200-239 130-159 160-189 160-189
High >=240 160-189 190-219 190-219
Very high >=190 >=220 >=220

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020
Risk Groups Treatment Goals Consider Drug Therapy
LDL-C (mg/dL) Non-HDL (mg/dL) LDL-C (mg/dL) Non-HDL (mg/dL)
Extreme Risk Group Category A <50 (Optional goal ≤30) <80 (Optional goal ≤60) ≥50 ≥80
Extreme Risk Group Category B ≤30 ≤60 >30 >60
Very High Risk <50 <80 ≥50 ≥80
High Risk <70 <100 ≥70 ≥100
Moderate Risk <100 ≥100 ≥130
Low risk <100 ≥130* ≥160*
*After an adequate non-pharmacological intervention for at least 3 months

Clinical Significance
• Measurements in the same patient can show physiological and analytical variations. Three serial samples 1 week apart are
recommended for Total cholesterol, Triglycerides , HDL & LDL Cholesterol.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 4 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 01:42 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 07:56 PM
Referral Doctor Self Report Status Provisional
Lipid Profile
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

• Friedewald equation to calculate LDL cholesterol is most accurate when triglyceride level is < 400mg/dL. Measurement
of Direct LDL Cholesterol is recommended when Triglyceride level is >400 mg/dL.
• Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular
Disease (ASCVD) risk factors, especially lipid profile. This should be done earlier if there is a family history of premature heart
disease, dyslipidemia, obesity, or other risk factors.
• Lipid association of India recommends LDL-C as the primary target and non-HDL-C as a co-primary target, for lipid-lowering therapy.
• Non-HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, VLDL & VLDL remnants,
Chylomicron remnants and Lp(a).
• Apo B measurement is recommended in high-risk subjects after LDL-C and non-HDL-C goals have been achieved.
• Additional testing for Apolipoprotein B, hsCRP, Lp(a ) and LP-PLA2 should be considered among patients with moderate risk
for ASCVD for risk refinement.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 5 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 01:42 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 07:56 PM
Referral Doctor Self Report Status Provisional
Liver Function Test (LFT)
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Bilirubin Total 0.48 mg/dL 0.3-1.2

Method: DPD Diazotization

Bilirubin Direct 0.11 mg/dL 0.0-0.20

Method: DPD Diazotization

Bilirubin Indirect 0.37 mg/dL 0 - 0.8

Method: Calculated

Clinical Significance : Total Bilirubin

• Prehepatic Jaundice : Diseases of prehepatic origin with predominantly unconjugated hyperbilirubinemia
a) Corpuscular haemolytic anemias e.g. thalassemia and sickle cell anemia;
b) Extracorpuscular haemolytic anemia e.g. blood transfusion reaction due to ABO and Rh incompatibility;
c) Neonatal jaundice and haemolytic disease of the newborn.
• Hepatic Jaundice : Diseases of hepatic origin with predominantly conjugated hyperbilirubinemia include acute and chronic viral hepatitis,
liver cirrhosis and hepatocellular carcinoma.
• Post hepatic Jaundice: Diseases of post-hepatic origin with predominantly conjugated hyperbilirubinemia include extrahepatic cholestasis
and liver transplant rejection.
• Chronic congenital hyperbilirubinemias include the unconjugated hyperbilirubinemias Crigler-Najjar syndrome and Gilbert's syndrome
as well as the conjugated hyperbilirubinemias Dubin-Johnson syndrome and Rotor syndrome.

Clinical Significance : Direct Bilirubin

• The assessment of direct bilirubin is helpful in the determination of hepatic and post-hepatic jaundice.

Alanine Aminotransferase (ALT/SGPT) 8 IU/L 0-35

Method: UV Kinetic IFCC without P5P

Clinical Significance : Alanine Aminotransferase (ALT)

• Elevated serum ALT activity is mainly regarded as an indicator of parenchymal liver disease.
• Increased serum levels indicate deterioration in the integrity of the hepatocyte plasma membrane.
• ALT has greater diagnostic sensitivity for hepatobiliary disease than AST.
• Activities >50 times the upper reference limit are mainly associated with acute viral hepatitis, acute disorders of liver perfusion and
acute liver necrosis due to ingestion of toxins including paracetamol and carbon tetrachloride.
• Markedly elevated serum ALT levels is found in hepatitis, mononucleosis and cirrhosis.
• Levels greater than 15 times the upper reference limit are indicative of acute hepatocellular necrosis of viral, toxic or circulatory origin.

Aspartate Aminotransferase (AST/SGOT) 15 IU/L 0-35

Method: UV Kinetic IFCC without P5P

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 6 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 01:42 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 07:56 PM
Referral Doctor Self Report Status Provisional
Liver Function Test (LFT)
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Clinical Significance : Aspartate Aminotransferase (AST)

• Measurement of AST is indicated in the diagnosis, differentiation and monitoring of hepatobiliary disease, myocardial infarction and
skeletal muscle damage.
• AST levels may be increased in viral hepatitis and liver disease associated with hepatic necrosis, with 20 to 50 fold elevations frequently
encountered.
• The evaluation of AST activity in relation to ALT (De Ritis ratio; AST/ALT) is a useful indicator of liver damage.
• Ratios > 1.0 are indicative of severe liver disease, usually involving necrosis.
• Ratios < 1.0 are indicative of mild liver damage associated with inflammatory conditions.

Alkaline Phosphatase (ALP) 92 IU/L 30-120

Method: pNPP AMP Buffer IFCC

Clinical Significance : Alkaline Phosphatase (ALP)

• Increases in total ALP are either due to physiological causes, or are caused by diseases of the liver or bone.
• Physiological increases in ALP are found in pregnancy from the 2nd trimester onwards due to placental ALP, in growing children due to
bone ALP and postprandially in individuals with blood groups B and O, who are secretors of blood group substance H (intestinal ALP).
• Most common cause of elevated ALP is hepatobiliary disease.
• Primary bone diseases with elevated ALP : osteomalacia, osteogenesis imperfecta, vitamin D intoxication and primary bone tumours.
• Secondary bone diseases with elevated ALP : skeletal metastases, and in diseases such as multiple myeloma, acromegaly, renal
insufficiency, hyperthyroidism, ectopic ossification, sarcoidosis, bone tuberculosis and healing fractures.

Protein - Serum 6.3 gm/dL 6.6-8.3

Method: Biuret Serum blank End point

Albumin-serum 3.4 gm/dL 3.5-5.2

Method: Bromocresol Green

Globulin-Serum 2.9 gm/dL 2.2 - 4

Method: Calculated

Albumin/Globulin Ratio 1.2 1.2-2.5

Method: Calculated

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 7 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 01:42 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 07:56 PM
Referral Doctor Self Report Status Provisional
Liver Function Test (LFT)
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Clinical Significance : Albumin

• Measurements of albumin concentrations are vital to the understanding and interpretation of calcium and magnesium levels
because these ions are bound to albumin, and decreases of albumin are directly responsible for depression of their concentrations.
• Hyperalbuminemia is infrequent and is caused by severe dehydration and excessive venous stasis.
• Hypoalbuminemia due to impaired synthesis : Liver disease or in protein deficient diets.
• Hypoalbuminemia due to increased catabolism : Tissue damage and inflammation
• Hypoalbuminemia due to reduced absorption of amino acids : Malabsorption syndromes or malnutrition.
• Hypoalbuminemia due to protein loss : Nephrotic syndrome, enteropathy or burns.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 8 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 12:18 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 02:44 PM
Referral Doctor Self Report Status Provisional
Complete Urine Examination (CUE)
Department of Clinical Pathology
SampleType: URINE

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

PHYSICAL EXAMINATION
Colour Pale yellow Pale Yellow
Method: Physical

Appearance Clear Clear

Method: Physical

CHEMICAL EXAMINATION
Reaction and PH 5.5 4.6 - 8
Method: Double Indicator

Specific Gravity 1.008 1.003 - 1.035

Method: Bromothymol Blue

Glucose Negative Negative

Method: Glucose oxidase Peroxidase

Protein Negative Negative

Method: Protein error of Indicator

Blood Negative Negative

Method: Peroxidase like activity

Ketones Negative Negative

Method: Sodium Nitroprusside

Bilirubin Negative Negative

Method: Dichloroaniline diazonium

Leukocytes Negative Negative

Method: 3hydroxy 5phenylpyrrole diazonium

Urobilinogen Normal Normal

Method: Ehrlichs reaction

Nitrites Negative Negative

Method: Diazonium

MICROSCOPIC EXAMINATION
Epithelial Cells 2-3 2-5

Pus Cells 1-2 2-3

RBCs Nil Nil

Crystals NIL Nil

Casts NIL Nil

Others NIL

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 9 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 12:20 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 01:55 PM
Referral Doctor Self Report Status Provisional
Complete Blood Picture (CBP)
Department of Haematology
SampleType: Whole Blood EDTA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Hemoglobin 11.7 gm/dL 12 - 15

Method: SLS Hemoglobin Detection

Hematocrit 36.4 % 36 - 46
Method: RBC Pulse Height Detection

RBC COUNT 4.04 Millions/ 3.8 - 4.8

Method: HD focussed DC Detection cumm

RED CELL INDICES .

Method: Calculated from RBC HB and HCT

MCV 90.1 fL 83 - 101

MCH 29.0 pg 27 - 32

MCHC 32.1 gm/dL 31.5 - 34.5

RDW-CV 13.6 % 7.5 - 15.5

Total Leucocyte Count 7220.0 /cumm 4000 - 10000

Method: Flow cytometry WNR channel

DIFFERENTIAL LEUCOCYTE COUNT .

Method: Flow cytometry Calculated

Neutrophils 56.5 % 40 - 80

Lymphocytes 35.2 % 20 - 40

Monocytes 4.4 % 2 - 10

Eosinophils 3.6 % 1-6

Basophils 0.3 % 0-1

ABSOLUTE LEUCOCYTE COUNT .

Method: Flow cytometry WDF channel

Absolute Neutrophil Count 4080.0 /cumm 2000 - 7000

Absolute Lymphocyte Count 2540.0 /cumm 1000 - 3000

Absolute Monocyte Count 320.0 /cumm 200 - 1000

Absolute Eosinophil Count 260.0 /cumm 200 - 500

Absolute Basophil Count 20.0 /cumm 20 - 100

Platelet Count 2.48 Lakhs/ 1.5-4.0

Method: HD focussed DC Detection cumm

Mean Platelet Volume 9.8 fL 7 - 11

Method: Calculated from PCT and Platelet count

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 10 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 12:20 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 01:55 PM
Referral Doctor Self Report Status Provisional
Complete Blood Picture (CBP)
Department of Haematology
SampleType: Whole Blood EDTA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

PERIPHERAL SMEAR EXAMINATION .

Method: Microscopy of Leishman Stained Smear

RBCs Normocytic Normochromic.

WBCs Normal count & Differential.

Platelets Adequate in number & Normal in morphology.

Hemoparasites No Parasite Found.

Impression NORMAL STUDY

Critical limits (alert values) are widely adopted as a standard of good laboratory practice and are defined as test parameter results that
are outside the normal range to a degree that constitute an immediate health risk to the individual or require immediate action on the
part of the ordering physician to avert significant patient morbidity or mortality
Parameter Units Critically Low Critically High
Hemoglobin (birth to 6 days) g/dL <= 12.0 >= 22.0
Hemoglobin (6 days to Adult) g/dL <= 7.0 >= 21.0
Hematocrit (birth to 6 days) % <= 35.0 >= 65.0
Hematocrit (6 days to Adult) % <= 21.0 >= 65.0
Total Leucocyte count /cu.mm <= 500.0 >= 50,000.0
Absolute Neutrophil count /cu.mm <= 500.0
Platelet count Lakhs/cu.mm <= 0.20
Note: In addition presence of blasts and hemoparasites (Eg. Malarial parasite) on slide review are critical alerts
Note:
1. Flagged results of Absolute Eosinophil count, Absolute Basophil count & Absolute Monocyte count below the biological reference intervals
are clinically insignificant.
2. As per the recommendations of International Council for Standardization in Hematology (ICSH), the Differential Leucocyte counts are
additionally being reported as Absolute numbers of each cell per unit volume of blood.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 11 of 13

Name Sayyad Hameeda bee Order PTGOC2600342438
Age / Sex 71 years / Female Sample Drawn 22-Jul-25 / 08:09 AM
Contact 7675949007 Sample Accepted 22-Jul-25 / 12:20 PM
Collection Centre INTGHYD95295 Sample Reported 22-Jul-25 / 01:55 PM
Referral Doctor Self Report Status Provisional
Erythrocyte Sedimentation Rate (ESR)
Department of Haematology
SampleType: Whole Blood EDTA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Erythrocyte Sedimentation Rate (ESR) 22 mm 0-35

Method: Capillary Quantitative Photometry

Clinical Significance
a) ESR is used as a screening test to detect the presence of a systemic disease; however, a normal test does not exclude malignancy or
other serious disease, although it does rule out temporal arteritis or polymyalgia rheumatica. It is limited by low sensitivity.
b) CRP is superior to ESR because it is more sensitive and reflects a more rapid change in the patient’s condition.
c) Finding a normal ESR in patients with paraproteinemia suggests the development of hyperviscosity syndrome.
d) ESR is also used to monitor the course or response to therapy of diseases if greatly accelerated initially.
e) Finding a much accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a severe
systemic disease, especially paraproteinemias, disseminated malignancies, connective tissue diseases, and bacterial endocarditis.

Interpretation of results
ESR Increased in ESR Decreased in
a) Infections a) Polycythemia vera
b) Vasculitis, including temporal arteritis b) Sickle cell anemia
c) Inflammatory arthritis c) Congestive Heart Failure
d) Renal disease d) Typhoid and undulant fever
e) Anemia e) Peptic ulcer
f) Malignancies and plasma cell dyscrasias f) Acute allergy
g) Tissue injury, including myocardial infarction g) Malarial paroxsym

*** END OF THE REPORT ***

M Jagannath Dr G Srinivas H Laxminarayana Mr G Arun

Verified by Director-Lab Services Regd no: TSMC-49913 Verified by Verified by

M Nageshwar Rao
Verified by

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MEDPLUS HEALTH SERVICES LIMITED H No 11-5-56, Survey No 257 and 258/1, Opp IDPL Railway siding, Moosapet, Kukatpally, Hyderabad, Telangana, 500037

CIN: L85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 12 of 13

Page 13 of 13